Formestane Versus Megestrol Acetate in Postmenopausal Breast Cancer Patients After Failure of Tamoxifen: a Phase III Prospective Randomised Cross Over Trial of Second-line Hormonal Treatment (SAKK 2090)

Author： Swiss Group for Clinical Cancer Research SAKK   Thurlimann B.   Castiglione M.   Hsu-Schmitz S.F.   Cavalli F.   Bonnefoi H.   Fey M.F.   Morant R.   Lohnert T.   Goldhirsch A.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.33, Iss.7, 1997-06, pp. : 1017-1024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality of Life in Postmenopausal Patients with Breast Cancer after Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-line Hormonal Treatment

By Bernhard J.   Castiglione-Gertsch M.   Schmitz S.-F.H.   Thurlimann B.   Cavalli F.   Morant R.   Fey M.F.   Bonnefoi H.   Goldhirsch A.   Hurny C.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

A Randomised Phase III Cross-over Study of Tamoxifen Versus Megestrol Acetate in Advanced and Recurrent Breast Cancer

By Stuart N.S.A.   Warwick J.   Blackledge G.R.P.   Spooner D.   Keen C.   Taylor A.R.   Tyrell C.   Webster D.J.T.   Earl H.  

European Journal of Cancer, Vol. 32, Iss. 11, 1996-10 ,pp. : 1888-1892

Elsevier

Access to resources Recommend Favorite

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

A Randomised Trial Comparing Two Doses of the New Selective Aromatase Inhibitor Anastrozole (Arimidex) With Megestrol Acetate in Postmenopausal Patients With Advanced Breast Cancer

By Berry J.   Sahlberg P.   ARIMIDEX Study Group   Jonat W.   Howell A.   Blomqvist C.   Eiermann W.   Winblad G.   Tyrrell C.   Mauriac L.   Roche H.   Lundgren S.   Hellmund R.   Azab M.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 404-412

Elsevier

Access to resources Recommend Favorite

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

By Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 718-724

Informa Healthcare

Access to resources Recommend Favorite